CLINICAL CHEMISTRY ANALYZERS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Key Developments

• In July 2024, Beckman Coulter Diagnostics introduced the DxC 500i Clinical Analyzer, an integrated clinical chemistry and immunoassay analyzer designed to meet the needs of both satellite and core laboratories. This new analyzer leverages Beckman Coulter's common reagents and consumables, providing commutable patient results and strategic benefits for healthcare networks. Kathleen Orland, Senior Vice President at Beckman Coulter Diagnostics, highlights that the DxC 500i offers reliable performance, simplicity, and trusted clinical quality, making it ideal for low-volume labs, standalone laboratories, and community hospitals.
• In July 2023, Beckman Coulter Diagnostics received the U.S. FDA clearance for the DxC 500 AU Chemistry Analyzer, an automated system tailored for small-to-medium-sized laboratories. This analyzer, equipped with standardized assays, improves clinical decision-making and patient outcomes with proven Six Sigma performance, enhancing efficiency and reliability in diagnostic testing.
• In May 2023, Siemens Healthineers introduced the Atellica HEMA 570 and 580 Analyzers, designed for high-volume hematology testing. These solutions offer intuitive interfaces, multi-analyzer automation connectivity, and rules-based testing to streamline workflows and deliver fast, reliable results for physicians and patients.
• In March 2023, Thermo Fisher Scientific completed the acquisition of The Binding Site Group for USD 2.8 billion (£2.3 billion). This acquisition strengthens Thermo Fisher's Specialty Diagnostics segment, particularly in oncology testing for multiple myeloma.
• In May 2022, Mindray introduced the BS-600M, a robust and efficient chemistry analyzer designed to enhance productivity, efficiency, and reliability for medium-volume laboratories.